1 Title: The Effect of Metformin Treatment on the Circulating Proteome

2

3	Ben Connolly*, Laura McCreight*, Roderick C Slieker*, Khaled F Bedair, Louise Donnelly,
4	Juliette A de Klerk, JWJ Beulens, PM Elders, IMI-DIRECT, IMI-RHAPSODY, Göran
5	Bergström, Mun-Guan Hong, Robert W. Koivula, Paul W. Franks, Leen 't Hart [†] , Jochen M
6	Schwenk†, Anders Gummesson†, Ewan R Pearson†
7	
8	BC-b.w.connolly@dundee.ac.uk, LMcC- laura.mccreight@nhs.scot, KFB-
9	k.f.e.bedair@dundee.ac.uk, LD- l.y.donnelly@dundee.ac.uk, ERP-
10	e.z.pearson@dundee.ac.uk: Division of Population Health & Genomics, School of Medicine,
11	University of Dundee, UK.
12	MGH- mun-gwan.hong@scilifelab.se, JMS- jochen.schwenk@scilifelab.se: Department of
13	Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
14	RCS- r.c.slieker@lumc.nl: Department of Cell and Chemical Biology, Leiden University
15	Medical Center, Leiden, the Netherlands
16	LtH- lmthart@lumc.nl: Department of Cell and Chemical Biology, Leiden University
17	Medical Center, Leiden, the Netherlands
18	Department of Epidemiology and Data Sciences, Amsterdam University Medical Center,
19	Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
20	Health Behaviors & Chronic Diseases Research Program & Personalised Medicine Research
21	Program, Amsterdam Public Health, Amsterdam, The Netherlands
22	Department of Biomedical Data Sciences, Section Molecular Epidemiology, Leiden
23	University Medical Center, Leiden, The Netherlands

Page | 1

2	л
4	4

24	
25	RK- robert.koivula@med.lu.se: Oxford Centre for Diabetes, Endocrinology and Metabolism,
26	Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
27	Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Department of
28	Clinical Medicine, Lund University, Malmo, Sweden.
29	
30	JWB-j.beulens@amsterdamumc.nl: Department of Epidemiology & Data Science,
31	Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands
32	Amsterdam Public Health, Amsterdam Cardiovascular Sciences research institutes,
33	Amsterdam, The Netherlands
34	JAdK-j.a.de_klerk@lumc.nl: Department of Cell and Chemical Biology, Leiden University
35	Medical Center, Leiden, the Netherlands / Department of Internal Medicine (Nephrology),
36	Leiden University Medical Center, Leiden, the Netherlands
37	AG- anders.gummesson@vgregion.se: Region Västra Götaland, Sahlgrenska University
38	Hospital, Department of Clinical Genetics and Genomics, Gothenburg, Sweden.
39	GB- goran.bergstrom@hjl.gu.se: Region Västra Götaland, Sahlgrenska University Hospital,
40	Department of Clinical Physiology, Gothenburg, Sweden.
41	AG, GB: Department of Molecular and Clinical Medicine, Institute of Medicine, Sanigrenska
42	Academy, University of Gothenburg, Gothenburg, Sweden.
43	
44	*joint first author; †joint senior author

Adress for correspondence 45

- 46 Ewan Pearson
- 47 Division of Population Health & Genomics
- 48 School of Medicine
- 49 University of Dundee
- 50 DD1 9SY
- 51 +44 1382 383387
- 52 <u>e.z.pearson@dundee.ac.uk</u>
- 53 Word Count- 3986, 4 Figures

54

55 Highlights

56	•	In the most comprehensive proteomic analysis of metformin exposure to date, we
57		showed 97 proteins to be associated with metformin exposure in at least one study.
58	٠	14 proteins were consistently associated with metformin exposure in 2 or more
59		platforms or studies.
60	•	Gene enrichment analysis shows that the strongest protein set is of intestinal origin.
61	•	These data provide further insight into the mechanism of action of metformin,
62		potentially identify novel targets for diabetes treatment and highlight the need to
63		account for metformin exposure in proteomic studies and where protein biomarkers
64		are used for clinical care.
65		
66	Object	ive
67	Metfor	min is one of the most used drugs worldwide. However, its mechanism of action

remains uncertain. Given the potential to reveal novel insights into the pleiotropic effects of

69 metformin treatment, we aimed to undertake a comprehensive analysis of circulating

70 proteins.

71 Research Design and Methods

72 We analysed 1195 proteins using the SomaLogic platform in 1175 participants, using cross-

rectional data from the GoDARTS and DCS cohorts; 450 proteins using the Olink platform in

74 784 participants, using cross-sectional data from IMI-DIRECT; and combined longitudinal

data from the IMPOCT, RAMP and S3WP-T2D cohorts with 372 proteins in 98 participants

vising the Olink platform. Finally, we performed systems level analysis on the longitudinal

77 OLINK data to identify any possible relationships for the proteins changing concentration

78 following metformin exposure.

79 Results

80 Overall, 97 proteins were associated with metformin exposure in at least one of the studies

81 (P_{adj}<0.05), and 10 proteins (EpCAM, SPINK1, t-PA, Gal-4, TFF3, TF, FAM3C, COL1A1,

82 SELL, CD93) were associated in two independent studies. Four proteins, REG4, GDF15,

83 REG1A, and OMD were consistently associated across all studies and platforms. Gene-set

84 enrichment analysis revealed that the effect of metformin exposure was on intestinal tissues.

85 In the longitudinal analysis 18% of proteins were significantly altered by metformin.

86 Conclusions

87 These data provide further insight into the mechanism of action of metformin, potentially

identifying novel targets for diabetes treatment, and highlight the need to account for

89 metformin exposure in proteomic studies and where protein biomarkers are used for clinical

90 care where metformin treatment will generate false positive results.

92

- 93
- 94

95	Metformin works by several mechanisms known to have a positive impact on inflammation
96	and metabolism; it does this by primarily acting on the liver and the $gut(1)$, however the exact
97	molecular mechanisms remain uncertain. The increasing availability of deep molecular
98	phenotyping in patients treated with metformin, including genomic, transcriptomic,
99	metabolic, proteomic and metagenomic data, offers the opportunity to gain further
100	mechanistic insight into the mechanism of action of metformin in humans. Genome-wide
101	association studies (GWAS) have provided some insight into the mechanism of action of
102	metformin in people with type 2 diabetes(2). In GWAS studies, two genetic variants have
103	been reproducibly associated with glycaemic response to metformin – rs11212617 at a locus
104	including ATM(3) and rs8192675, intronic in SLC2A2, associated with altered expression of
105	GLUT2(4). Other studies have reported on epigenetic markers(5), the transcriptome(6), the
106	metabolome(7) and the microbiome(8) altering glycaemic response, weight change or
107	intolerance in people with diabetes.
108	There are limited proteomic studies of metformin exposure, and these have largely been

109 targeted or using small panels. A reproducible robust association has been described between

110 metformin exposure and serum Growth differentiation factor 15 (GDF15) concentrations.

111 This was first identified in a Luminex panel measuring 237 proteins from the ORIGIN

study(9). This has been subsequently replicated with mechanistic rodent studies establishing

that metformin associated increase in GDF15 resulted in a reduction in food intake and body

114 weight and that the origin of GDF15 associated with metformin exposure was the

intestine(10). More recently, Gummesson et al carried out a more comprehensive proteomicPage | 5

116	analysis following metformin treatment. This further showed that GDF15 was increased
117	following metformin treatment in addition to identifying other proteins significantly altered
118	by metformin exposure; for example, EpCAM was reduced in those treated with
119	metformin(11). Given the potential for proteomic signatures after metformin exposure to
120	inform on its mechanism of action and identify novel diabetes drug targets, here we extend
121	these analyses, including the study by Gummesson et al. but greatly increasing the number of
122	individuals included to 2,057 and increasing the number of studies to incorporate both cross-
123	sectional and longitudinal studies of metformin exposure, using two commonly used
124	proteomic methods - Olink and SomaLogic.
125	Research Design and Methods
126	
127	Cohorts
127 128	Cohorts GoDARTS: The Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) is a
127 128 129	Cohorts GoDARTS: The Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) is a cohort of ~8,000 individuals with T2D(12). Laboratory measurements were non-fasted. For
127 128 129 130	Cohorts GoDARTS: The Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) is a cohort of ~8,000 individuals with T2D(12). Laboratory measurements were non-fasted. For SomaLogic analysis, samples from 599 patients were selected age >35 years, GAD antibody
127 128 129 130 131	Cohorts GoDARTS: The Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) is a cohort of ~8,000 individuals with T2D(12). Laboratory measurements were non-fasted. For SomaLogic analysis, samples from 599 patients were selected age >35 years, GAD antibody negative, with blood sampled close to diagnosis (median diabetes duration 1.4 years).
127 128 129 130 131	Cohorts GoDARTS: The Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) is a cohort of ~8,000 individuals with T2D(12). Laboratory measurements were non-fasted. For SomaLogic analysis, samples from 599 patients were selected age >35 years, GAD antibody negative, with blood sampled close to diagnosis (median diabetes duration 1.4 years). DCS: The Hoorn Diabetes Care System (DCS) cohort is a prospective cohort with currently
127 128 129 130 131 132 133	Cohorts GoDARTS: The Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) is a cohort of ~8,000 individuals with T2D(12). Laboratory measurements were non-fasted. For SomaLogic analysis, samples from 599 patients were selected age >35 years, GAD antibody negative, with blood sampled close to diagnosis (median diabetes duration 1.4 years). DCS: The Hoorn Diabetes Care System (DCS) cohort is a prospective cohort with currently over 14,000 individuals with routine care data. In 2008–2014, additional blood sampling was
127 128 129 130 131 132 133 134	Cohorts GoDARTS: The Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) is a cohort of ~8,000 individuals with T2D(12). Laboratory measurements were non-fasted. For SomaLogic analysis, samples from 599 patients were selected age >35 years, GAD antibody negative, with blood sampled close to diagnosis (median diabetes duration 1.4 years). DCS: The Hoorn Diabetes Care System (DCS) cohort is a prospective cohort with currently over 14,000 individuals with routine care data. In 2008–2014, additional blood sampling was done in 5500 participants, who provided written informed consent. These samples were used
127 128 129 130 131 132 133 134 135	Cohorts GoDARTS: The Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) is a cohort of ~8,000 individuals with T2D(12). Laboratory measurements were non-fasted. For SomaLogic analysis, samples from 599 patients were selected age >35 years, GAD antibody negative, with blood sampled close to diagnosis (median diabetes duration 1.4 years). DCS: The Hoorn Diabetes Care System (DCS) cohort is a prospective cohort with currently over 14,000 individuals with routine care data. In 2008–2014, additional blood sampling was done in 5500 participants, who provided written informed consent. These samples were used for this study. For SomaLogic analysis, samples from 576 patients were selected age >35
127 128 129 130 131 132 133 134 135 136	Cohorts GoDARTS: The Genetics of Diabetes Audit and Research Tayside Study (GoDARTS) is a cohort of ~8,000 individuals with T2D(12). Laboratory measurements were non-fasted. For SomaLogic analysis, samples from 599 patients were selected age >35 years, GAD antibody negative, with blood sampled close to diagnosis (median diabetes duration 1.4 years). DCS: The Hoorn Diabetes Care System (DCS) cohort is a prospective cohort with currently over 14,000 individuals with routine care data. In 2008–2014, additional blood sampling was done in 5500 participants, who provided written informed consent. These samples were used for this study. For SomaLogic analysis, samples from 576 patients were selected age >35 years, GAD antibody negative, with blood sampled close to diagnosis (median diabetes

137 duration 2.6 years)(13).

138 **DIRECT:** This cohort included 784 patients with recently diagnosed type 2 diabetes. The 139 mean age at inclusion was 62 years with the youngest 35 years at baseline, which should 140 exclude any individuals with MODY. Participants were diagnosed within two years before 141 recruitment, were on lifestyle and/or metformin treatment only, and had glycated 142 haemoglobin (HbA_{1c}) < 60.0 mmol/mol (< 7.6%) within previous three months(14). 143 **S3WP-T2D**: This study was carried out to elucidate the changes in the proteome in the early 144 stages of diabetes and how the proteome is affected by diabetes treatment including 145 metformin(11). 52 previously undiagnosed patients were identified as having type 2 diabetes 146 from a screening program and as a result, were recruited for the study. Patients were excluded 147 if they had a pre-existing disease which would affect their ability to participate, severe 148 hyperglycaemia needing hospital attention or immediate insulin therapy, or a major surgical 149 procedure or trauma within 4 weeks. Included patients were treated for diabetes via first line 150 therapy; weight management and exercise with or without metformin which was decided by a 151 doctor. Protein levels in the blood were measured at baseline, one month and 3 months. Of 152 the 52 participants, 51 completed the 3 month follow up visit and for 3 patients plasma 153 samples were not available for the 1 month visit. This left data for 48 patients to be analysed. 154 **IMPOCT**: The IMPOCT study was designed to investigate the impact of the OCT1 genotype 155 and OCT1 inhibiting drugs on an individual's ability to tolerate metformin. For our analysis, 156 only the data from when individuals were treated with metformin and placebo was utilised, 157 and not data from individuals on OCT1 inhibiting drugs. 38 healthy participants without 158 diabetes were recruited for this study. They were on metformin for 4 weeks, titrated to a max 159 dose of 1000mg BD which they took for the final week of the study. Protein levels in the 160 blood were measured at baseline and after the 4 weeks of metformin treatment.

161	RAMP : The RAMP study was designed to investigate the response of individuals with ataxia
162	telangiectasia to metformin and pioglitazone. For our analysis, we only utilised data from
163	control patients (without ataxia telangiectasia) on metformin (not pioglitazone). 12 non-
164	diabetic, healthy controls, who had never been on metformin before were started on the drug.
165	They were treated with metformin for 8 weeks, titrated to a maximum dose of 1000mg BD
166	which they were on for the final 4 weeks of the study. Protein levels in the blood were
167	measured at baseline and after the 8 weeks of metformin treatment.
168	Proteomics assays
169	We used two complementary affinity proteomics approaches to determine the relative levels
170	of circulating proteins in blood samples(15). Each technology is capable to measure
171	thousands of proteins, but a list of 500 proteins have been described to correlate with high
172	confidence between the two platforms. Cross-sectional data from GoDARTS and DCS was
173	analysed using SomaLogic; 1195 proteins were measured and included in the analysis after
174	standardized QC. Olink panels were used as follows:
175	DIRECT: The proteins were measured on five Olink panels: Cardiometabolic,
176	Cardiovascular II, Cardiovascular III, Development, Metabolism. After proteins were
177	removed following quality control, this left 450 proteins to be analysed.
178	S3WP-T2D: The proteins were measured on eleven Olink panels (Cardiometabolic, Cell
179	Regulation, Cardiovascular II, Cardiovascular III, Development, Immune Response,
180	Oncology II, Inflammation, Metabolism, Neurology, and Organ Damage).
181	IMPOCT. The proteins were measured on five Olink panels (Cardiometabolic,
182	Cardiovascular II, Cardiovascular III, Development and Metabolism).

183 RAMP. These proteins were measured on the same five Olink panels as the IMPOCT study

- 184 (Cardiometabolic, Cardiovascular II, Cardiovascular III, Development and Metabolism).
- 185 After proteins were removed following quality control and to ensure each protein was
- included in all three studies, 372 proteins were analysed in the combined analysis of S3WP-
- 187 T2D, IMPOCT and RAMP.

188 Statistical methods

189 RHAPSODY: GoDARTS and DCS

190 We undertook a linear regression for the biomarker as dependent variable, with metformin

191 exposure (Y/N), adjusted for age and gender. This was done for both DCS and GoDARTS

and then data were combined using random effects meta-analysis. A Bonferroni correction

193 was applied for the 1195 assays included in the analysis.

194 In both cohorts we then analysed the protein levels of the proteins significantly associated

195 with metformin exposure, in relation to the daily metformin dose used by the participants.

196 Protein levels were used as endpoints in linear regression analyses and metformin dose as

197 predictor with adjustment for gender, age, BMI and HbA1c levels. Persons not using

198 metformin were excluded prior to this analysis. Metformin dose was binned per 500mg to

ease the interpretation of the data. i.e. the beta is the change in protein level per extra 500mg

- 200 tablet of metformin. Similar results were obtained in analyses where metformin dose was
- 201 included as a continuous variable.

202 DIRECT

A linear mixed model was applied using the lmer function of the R package lme4. In this

204 model, the Olink NPX data was adjusted by information related to the donor (age at

sampling, sex) the sampling event (date, centre) as well as technical aspects (assay plate).
 Page | 9

206 Combined analysis: S3WP-T2D, IMPOCT and RAMP

207 The longitudinal data from the S3WP-T2D study described by Gummesson et al(11) were combined with the longitudinal data from two Dundee studies; IMPOCT and RAMP. In these 208 209 studies, Olink panels were used to measure proteins before and after metformin exposure. 210 Statistical analysis was performed using R Studio version 4.1.2. Proteins were analysed using 211 linear mixed models, with the R package LmerTest. The metformin dose and study name 212 were used as a fixed effect and the study individual was used as a random effect. Proteins 213 were removed so that the all the proteins present in the combined study data were analysed in 214 each of the three studies. This left 372 proteins to be analysed in the combined study data. 215 The metformin dose was simplified and allocated a 0 if the individual was not on metformin 216 and a 1 if the individual was on metformin treatment, regardless of the dose. P values were 217 adjusted using the Bonferroni method.

218 Adjusting for BMI with metformin exposure in S3WP-T2D and RAMP

219 It has been shown that the proteome can vary in response to weight gain and weight loss(16),

and that metformin is associated with weight loss. Consequently, a further linear mixed

221 model analysis was performed in which BMI was included as a covariate, in two of the three

222 longitudinal cohorts where weight was measured before and after metformin initiation.

223 The longitudinal data from S3WP-T2D and RAMP was combined, and the same 372 proteins

224 were analysed as before using a linear mixed model. Again, R package LmerTest was used

for this statistical analysis on R Studio version 4.1.2. Metformin dose, study name and BMI

were used as fixed effects, with the study individual as a random effect. P values were also

adjusted using the Bonferroni method.

228 Tissue specific gene expression and gene set analysis for proteins altered by metformin

229 exposure

- 230 Using Genotype Tissue Expression (GTEx) analysis we explored in what tissues the genes
- 231 encoding the proteins altered by metformin were expressed. We then used the enrichR
- 232 package in R to evaluate which tissues were enriched for, based upon the change in proteins
- in response to metformin treatment in the combined analysis of SCAPIS, IMPOCT and
- 234 RAMP. Proteins were converted to gene symbols and upregulated and downregulated
- 235 proteins were tested separately. An adjusted P-value smaller than 0.05 was considered
- 236 significant.

237 Causal inference- pQTL

238 Protein Quantitative Trait Loci (pQTL) analysis was carried out on 14 proteins that were

significantly associated with metformin exposure in two or more studies. pQTLs were

obtained from Sun et al. (BioRxiv, 2022). pQTLs in cis were filtered based on the UniProt

241 ID. pQTLs associated with proteins were compared to available traits in the OpenGWAS

242 database, but eQTLs, cancer-, peptide-, unknown metabolite traits were excluded. pQTLs and

243 identified traits were harmonised using the *harmonise_data* function in the TwoSampleMR

244 package. eQTLs were obtained from GTEx v8. EQTLs were considered significant if the p-

value was below GTEx's P-value threshold.

246 Results

247 Cross sectional metformin exposure and the SomaLogic platform. We first assessed

248 differences in protein levels measured using the SomaLogic platform in metformin treated

and untreated individuals from two cross-sectional studies as part of the IMI-RHAPSODY

consortium, where proteomic analysis was undertaken on two populations with type 2

251	diabetes	close to	diagnosis.	The	baseline	characteristics	of	the two	included cohort	s,
		•100•10	and gridding.		000001110	•	~ -			~,

252 GoDARTS and DCS cohort are shown in Supplementary Table 1. In the meta-analysis of

- these two datasets, 1195 proteins were analysed in 1175 subjects. After Bonferroni
- correction, levels of 34 proteins were significantly associated with metformin exposure
- 255 (Supplementary Table 2). The proteins where metformin exposure was associated with the
- largest difference in levels were REG4 (Beta=0.698, SE=0.084), GDF15 (Beta=0.657, SE
- 257 0.098), PYY (Beta=0.662, SE=0.147) and FGF19 (Beta=-0.519, SE=0.115). Given that this
- analysis was cross-sectional, and associations may not be causally associated with metformin
- 259 exposure we investigated the effect of metformin dose on protein concentrations, as a dose
- 260 effect would support a causal relationship between metformin exposure and protein

expression. Of the 34 proteins whose concentration was associated with metformin exposure

- adjusted for gender, age, BMI and HbA1c, a nominally significant (p<0.05) dose effect was
- seen for most proteins (25/34). After Bonferroni correction (p<0.05/34) increased metformin
- dose was associated with increased REG4, GDF15, CDH6 and PYY concentrations and
- decreased FGF19 and OMD concentrations (Supplementary Table 3).

266 Cross Sectional metformin exposure and the Olink platform. We then assessed

267 differences in protein levels measured using the Olink platform in individuals from the IMI-

268 DIRECT cohort of patients with type 2 diabetes diagnosed within the prior 2 years. Baseline

- characteristics of the IMI-DIRECT cohort are shown in Supplementary Table 1. In this
- study, 450 proteins were analysed in 784 subjects. After Bonferroni correction, 13 proteins
- 271 were significantly different between metformin users and non-users (Supplementary Table 4).
- 272 The largest signal was seen for a reduction in EpCAM, followed by an increase in SPINK1,
- 273 REG4 and GDF15).

274 Longitudinal metformin exposure and the Olink platform. We then analysed protein 275 concentrations longitudinally in individuals before metformin treatment and after metformin 276 initiation in 3 clinical trials. Baseline characteristics of included cohorts are shown in 277 Supplementary Table 1. Individual level data from the S3WP-T2D(11), IMPOCT and 278 RAMP studies were combined, and 372 proteins were analysed in 98 subjects using Olink 279 panels before and during metformin treatment. After Bonferroni correction, 68 proteins (18% 280 of measured proteins) were found to be significantly changed with metformin treatment 281 (Supplementary Table 5) and are represented in the volcano plot (Figure 1). The top 8 most 282 significant proteins are labelled in the figure and are as follows from most significant to least 283 significant: REG4, GDF-15, EpCAM, SPINK1, REG1A, LDL receptor, IGFBP-2 and t-PA. 284 We analysed the longitudinal data in males and females separately (Supplementary Table 10) 285 and show a consistent signal by sex for the top 6 most significant proteins. However, there 286 were differences, with 30 proteins including IGFBP-2 and t-PA being significantly changed 287 following metformin in males but not females. Similarly, CDH5, FAM3C, HAOX1 and 288 CCL15 were significantly changed after metformin in females but not males. 289 As metformin is associated with weight loss, we then evaluated whether the change in protein 290 concentration with metformin exposure was attenuated by BMI change in two of the 291 longitudinal cohorts where BMI was measured before and after metformin initiation (S3WP-292 T2D and RAMP). Complete attenuation of the change in protein concentration would 293 suggest that the difference is secondary to, or causal for, BMI change. As a positive control, 294 LEP (Leptin) is significantly reduced by metformin treatment, but adjusting for metformin 295 associated BMI change attenuates the effect by 61%, with loss of significance (p=0.15). 296 Supplementary Table 9 provides the results for the impact of metformin on protein 297 concentration with and without adjustment for BMI. Adjusting for BMI reduces the number 298 of Bonferroni significant proteins from 31 out of 372 proteins analysed across these two

299 studies to 21 proteins. Other than for leptin, the largest attenuation by adjusting for BMI was 300 seen with FUCA1 (84.2% attenuation); GUSB (29.5% attenuation); SELE (26.3% 301 attenuation), IGFBP2 (21% attenuation) and FCN2 (15% attenuation). Interestingly there 302 was no attenuation (0%) for GDF15, a protein previously reported to potentially mediate the 303 weight change caused by metformin(10). 304 305 Given the large number of proteins identified to be altered in our longitudinal analysis we 306 used GTEX(17), HPA(18), and STRING(19) to obtain system-level insights about possible 307 relationships for the 68 proteins identified. The tissue expression (mRNA and protein) from 308 GTEX of the top 68 proteins altered by metformin in the longitudinal analysis is shown in 309 Figure 2. Note that the expression reported here is tissue specific expression and does not 310 relate to metformin exposure. Expression of genes for proteins most changed by metformin 311 exposure were seen predominantly in the pancreas and intestine. In a gene set enrichment 312 analysis (Supplementary Table 7), upregulated proteins were enriched for colon (OR=20.4, Padi = 6.49×10^{-5}), based on overlap with REG4, REG1A, GDF15, TFF, SPINK1, CCL15, 313 314 PIGR and LGALS4. Downregulated proteins were enriched for omentum (OR=5.2, Padj = 2.93×10^{-6}) and liver (OR = 4.84, Padj = 7.52 \times 10^{-6}). We also explored possible protein 315 316 interactions using the default functions of the STRING database(19). This revealed that many 317 proteins have known or predicted interactions with each other (Figure 3). Among them, a group of proteins involved in cell adhesion (KEGG pathway, $P=2.8 \times 10^{-8}$) were particularly 318 319 connected based on experimental evidence. 320 321 Proteomic signatures of metformin across study and platform. Across the three studies,

there were 14 proteins where metformin exposure was associated with protein concentration

in at least two studies; the direction and effect sizes for these associations are shown in Figure

324 4. Four proteins were consistently associated with metformin exposure in the 3 studies 325 (including 2 cross-sectional and 1 longitudinal design) and across the two platforms (Olink 326 and SomaLogic); these were **REG4**, **GDF15**, **REG1A** and **OMD**. 8 additional proteins 327 were consistently associated with metformin exposure across the two studies using Olink; 328 these were EpCAM, SPINK1, t-PA, Gal-4, TFF3, TF, FAM3C, COL1A1. There were 2 329 proteins associated with metformin exposure common between the cross-sectional 330 SomaLogic and longitudinal Olink studies; these were SELL and CD93. Protein Quantitative 331 Trait Loci (pQTL) analysis was carried out for these 14 proteins. 11 proteins had at least one 332 associated pQTL, while Ep-CAM, SELL and CD93 did not (Supplementary table 8). There 333 were limited informative pQTL: trait associations that could be linked to metformin 334 exposure. A few examples include: where metformin and a pQTL both cause an increase in 335 GDF-15, neutrophil counts are increased, and monocyte counts are decreased; where 336 metformin lowers OMD, the A allele at rs35209758 which is also associated with lower 337 OMD is associated with an increase in Asporin and Hematopoietic progenitor cell antigen 338 CD34; where metformin increases FAM3C, the A allele at rs36198735 that is associated with 339 higher FAM3C is associated with higher heel bone mineral density.

340

341 Conclusions

We have undertaken the most comprehensive proteomic analysis of metformin exposure in people with and without diabetes to date. Our analysis spans different proteomic approaches and large cross-sectional studies and longitudinal studies with measures before and during metformin treatment. Overall, 97 proteins were associated with metformin exposure in at least one study. The concentration of 4 proteins (REG4, GDF15, REG1A and OMD) were associated with metformin exposure across all platforms and studies, and a further 10 proteins were consistently associated with metformin exposure in two independent studies.

Enrichment analysis shows that the strongest protein-set is of intestinal origin, consistent with the very high concentrations of metformin seen in intestinal epithelial cells. An increase in GDF-15(9) and a decrease in EpCAM(11) after metformin has been previously described and our results have confirmed these findings.

353 Our data add to the already robust literature that metformin increases serum GDF-15. GDF-

15 is a protein that increases in concentration due to cellular stress caused by mitochondrial

dysfunction, hypoxia, and exercise(20). It has been previously shown that the intestine

356 (particularly the lower small intestine and colon) was a main site of increased GDF-15

expression following metformin treatment(10). Although GDF-15 is associated with adverse

outcomes such as increasing age, cancer and cellular stress, pharmacologically increasing

359 GDF-15 could be beneficial. In wild-type mice treated with a high fat diet, metformin

360 prevented weight gain – an effect not seen in mice lacking GDF15 or lacking the GDF

receptor (GFRAL1)(10). These results establish in mice that the weight benefit observed

362 with metformin treatment was mediated by metformin associated increase in GDF15. In the

363 CAMERA trial of 74 non-diabetic participants there was a weak correlation between serum

364 GDF15 concentrations and weight loss in metformin treated individuals(10). However, our

data do not support a role for GDF15 in mediating the weight benefits of metformin as,

unlike for leptin, we show no attenuation of the GDF15 association with metformin when

367 adjusting for weight change.

368 Our tissue enrichment analysis identified a set of 8 proteins originating from the intestine as

the strongest tissue contributing to the metformin signature: **REG4**, **GDF15**, **REG1A**,

370 IGFBP2, **TFF3**, **SPINK1**, **Gal-4**, PIgR, with all but IGFBP2 and PlgR identified in two or

371 more studies. Two are Regenerating gene (REG) proteins – REG4 and REG1A – which are a

part of the calcium-dependent (C-type) lectin superfamily(21). These proteins have been

373	shown to be responsible for triggering cellular proliferation and are associated with some
374	malignancies such as colorectal cancer(22). REG4 can act as a marker for both
375	enteroendocrine cells and Paneth cells in the small intestine(23) and deep crypt secretory
376	cells (the colon equivalent of Paneth cells) in the colon(24), and has been shown to modulate
377	intestinal inflammation and is associated with ulcerative colitis and Crohn's disease(21).
378	Trefoil Factor Peptide 3 (TFF3) has a role in colonic epithelial homeostasis and response to
379	gastrointestinal inflammation and mucosal injury(25). Increased TFF3 in mouse hepatocytes
380	has been shown to cause inhibition of genes involved in gluconeogenesis such as PEPCK,
381	G6pc and PGC-1 α , reducing hepatic glucose output(26). Moreover, adenoviral
382	overexpression of TFF3 was shown to improve glucose tolerance and insulin sensitivity in
383	diabetic mice(26). In addition, TFF3 has been demonstrated to increase beta cell mass in rat
384	pancreatic islets(27). Serine Protease Inhibitor Kazal Type 1 (SPINK 1) is produced by
385	pancreatic acinar cells and has two main functions; acting as a trypsin inhibitor which acts to
386	protect the pancreas and acting as a cell growth and survival factor which leads to tumour
387	progression(28). Its role in pancreas protection is very important as mutations in the SPINK1
388	gene are associated with different forms of chronic pancreatitis(29).
389	The strong association of these intestinal-related proteins with metformin treatment may
390	simply reflect the high exposure of intestinal epithelial cells to metformin and does not
391	necessarily implicate these proteins as mediating any beneficial or potentially harmful effects
392	of metformin. A pQTL association with a trait could help inform on any causal benefit or
393	harm, although a pQTL in a non-metformin exposed state may differ from a pQTL under
394	metformin treatment. For example, metformin increases GDF-15 and a pQTL SNP
395	associated with increased serum GDF15 (in population level data) was associated with
396	increased neutrophil and lower lymphocytes. This is consistent with GDF15 being associated
397	with adverse conditions (age, cancer, cellular stress) but not consistent with the known effect

398	of metformin to lower neutrophil:lymphocyte ratio(30). Thus, although we do find pQTL
399	associated traits, these need to be interpreted with caution. However, whilst we cannot
400	conclude that the intestinal signature for the metformin proteome mediates metformin, it is
401	important to be aware of these strong associations as they could potentially be major
402	confounders in any proteomic analysis where some people may be metformin treated, and
403	clinically where a protein concentration is being used as a clinical biomarker, such as a
404	tumour marker. For example, REG4 is a postulated tumour marker for pancreatic
405	adenocarcinoma(31), gastric and colorectal cancer(32), EpCAM is a well-known tumour
406	marker associated with many cancers including colorectal, ovarian and breast cancers(33) and
407	REG1A has been recently associated with the development of pancreatic cancer(34).
408	The use of two proteomic platforms in both cross sectional and interventional studies,
409	totalling 2057 participants is a major strength of our study. However, we recognise there are
410	limitations. Firstly, newer proteomic panels include substantially more proteins (e.g. Olink
411	Explore HT measures >5300 proteins, and Somascan measures 7000 proteins). Secondly
412	whilst we combine 3 studies that measure proteins before and after metformin initiation, the
413	number of participants in these longitudinal studies remains small, especially when
414	considering the impact of metformin on BMI change. Finally, whilst we establish a large
415	number of robust signals and for some infer causal association, we don't establish a causal
416	mechanism for any of the associations. This will require further work with, for example,
417	mouse models as has been demonstrated for the mechanistic contribution of GDF15 to
418	metformin action(10).
419	In conclusion, we have carried out a comprehensive study on changes to the proteome

420 following metformin treatment. We identified many proteins that are increased or decreased

421 with metformin treatment, with enrichment for proteins originating from the intestine.

422 Overall, we have shown that the proteomic signature of metformin provides further insight Page | 18

423	into the mechanism of action, as well as highlighting the potential for false positive signals in
424	human proteomic studies if metformin treatment is not considered as an exposure.
425	Acknowledgements
426	We thank Ragna Häussler, Matilda Dale, the Affinity Proteomics Unit at SciLifeLab in
427	Stockholm for generating the Olink data. This project has received funding from the
428	Innovative Medicines Initiative Joint Undertaking 2, under grant agreement no. 115881
429	(RHAPSODY) and from the Innovative Medicines Initiative Joint Undertaking under grant
430	agreement no. 115317 (DIRECT), resources of which are composed of financial contribution
431	from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA
432	companies in kind contribution. There are no relevant conflicts of interest to disclose.
433	
434	Author contributions
435	BC, LM, RS, JMS, AG, LtH, ERP designed the study and wrote the manuscript. BC, KB,
436	LD, JK, RS, LtH analysed the data. MH, RK, PF and all co-authors critically reviewed the
437	final manuscript. ERP is the guarantor of this work and, as such, had full access to all the data
438	in the study and takes responsibility for the integrity of the data and the accuracy of the data
439	analysis.

440

441 Data Availability

All summary results for all 3 studies are provided in the supplementary excel file. The
generated individual level proteomic data and linked clinical data in RHAPSODY (DCS,
GoDARTS), DIRECT, S3WP-T2D, IMPOCT and RAMP are considered sensitive patient
data and cannot be made publicly available in compliance with the European privacy

regulations governed by GDPR and according to limitations included in the informed consents signed by the study participants. Data are available by request to the corresponding authors. Requests should include name and contact details of the person requesting the data, which molecular data and clinical variables are requested and the purpose of requesting the data.

451

452 Figure Legends

453 Figure 1 Effect of metformin on plasma protein levels. Volcano plot showing if protein 454 concentrations are significantly increased or decreased following metformin treatment in the 455 longitudinal Olink analysis. Estimate (beta coefficient) is plotted on the x axis and -log10 of 456 the unadjusted p-value (calculated from the linear mixed model) is plotted on the y axis. 457 Proteins with an adjusted p value (Bonferroni method) of less than 0.05 are represented by a 458 yellow dot and all other non-significantly changed proteins are represented by a grey dot. 459 Proteins which have an increased concentration following metformin treatment have a 460 positive effect size whereas proteins which have a decreased concentration following 461 metformin treatment have a negative effect size.

462

463 Figure 2: GTEx Analysis Showing the Tissues of Origin of Proteins significantly altered

464 **by metformin exposure**. The plot on the left shows the tissues where the mRNA

465 corresponding to the significant proteins are expressed. The plot on the right shows the tissue

466 of origin of the significant proteins. The plot in the middle visualises the significant proteins

- 467 based upon the longitudinal Olink analysis and whether they are increased or decreased
- following metformin treatment alongside their tissue of origin. Proteins/gene expression in
- this figure are ranked in decreasing order of significance. Only 59 of the 68 significant
- 470 proteins could be included in this analysis due to some proteins missing in the proteomics

- 471 data. The 9 proteins missing are SEMA7A, GAL-4, LEP, SELE, ADGRG2, CCL15,
- 472 CD300LG, TIMD4 and PGF.
- 473 Figure 3. A. Protein relationships for the 68 proteins associated with metformin
- 474 exposure in the longitudinal Olink study based on StringDB. A large numer of proteins
- showed experimentally validated interactions shown with with pink lines, were co-expressed
- 476 (black lines) or were mentioned together (green lines). Experimentally validated interactions
- are shown in thicker lines (pink, light blue).
- 478
- 479 Figure 4. Comparison of effect size across the three studies (Only proteins that are shared
- 480 in at least two studies are shown). X-axis, effect size; y-axis, protein.
- 481
- 482
- 483
- 484

485 **References**

- 486 1. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin.
- 487 Diabetologia. 2017 Sep 3;60(9).
- 488 2. Florez JC. The pharmacogenetics of metformin. Diabetologia. 2017 Sep;60(9):1648–
- 489 55.
- 490 3. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust
- 491 Case Control Consortium 2, Zhou K, Bellenguez C, Spencer CCA, Bennett AJ, et al.
- 492 Common variants near ATM are associated with glycemic response to metformin in
- 493 type 2 diabetes. Nat Genet. 2011 Feb;43(2):117–20.
- 494 4. Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, et al.
- 495 Variation in the glucose transporter gene SLC2A2 is associated with glycemic
 496 response to metformin. Nat Genet. 2016;48(9):1055–9.
- 497 5. García-Calzón S, Perfilyev A, Martinell M, Ustinova M, Kalamajski S, Franks PW, et
- 498 al. Epigenetic markers associated with metformin response and intolerance in drug-
- 499 naïve patients with type 2 diabetes. Sci Transl Med. 2020 Sep 16;12(561).
- 500 6. Ustinova M, Ansone L, Silamikelis I, Rovite V, Elbere I, Silamikele L, et al. Whole-
- 501 blood transcriptome profiling reveals signatures of metformin and its therapeutic

502 response. PLoS One. 2020;15(8):e0237400.

- 503 7. Xiao S, Li VL, Lyu X, Chen X, Wei W, Abbasi F, et al. Lac-Phe mediates the effects
 504 of metformin on food intake and body weight. Nat Metab. 2024 Mar 18;
- 505 8. Zhang Q, Hu N. Effects of Metformin on the Gut Microbiota in Obesity and Type
- 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2020 Dec;Volume 13:5003–14.
- 507 9. Gerstein HC, Pare G, Hess S, Ford RJ, Sjaarda J, Raman K, et al. Growth
- 508 Differentiation Factor 15 as a Novel Biomarker for Metformin. Diabetes Care. 2017
- 509 Feb 1;40(2):280–3.

Page | 22

510	10.	Coll AP. C	Then M.	Taskar P.	Rimmington D	. Patel S.	Tadross JA.	et al.	GDF15
010	10.		/11011 1/19	I donal I ,	1 thining ton D	, I acci Di	1441000011	, et an.	00110

- 511 mediates the effects of metformin on body weight and energy balance. Nature. 2020
 512 Feb 20;578(7795):444–8.
- 513 11. Gummesson A, Björnson E, Fagerberg L, Zhong W, Tebani A, Edfors F, et al.
- 514 Longitudinal plasma protein profiling of newly diagnosed type 2 diabetes.
- 515 EBioMedicine. 2021 Jan;63:103147.
- 516 12. Hébert HL, Shepherd B, Milburn K, Veluchamy A, Meng W, Carr F, et al. Cohort
- 517 Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). Int
- 518 J Epidemiol. 2018 Apr 1;47(2):380–381j.
- 519 13. van der Heijden AA, Rauh SP, Dekker JM, Beulens JW, Elders P, 't Hart LM, et al.
- 520 The Hoorn Diabetes Care System (DCS) cohort. A prospective cohort of persons with
- type 2 diabetes treated in primary care in the Netherlands. BMJ Open. 2017 May6;7(5):e015599.
- 523 14. Koivula RW, Forgie IM, Kurbasic A, Viñuela A, Heggie A, Giordano GN, et al.
- 524 Discovery of biomarkers for glycaemic deterioration before and after the onset of type
- 525 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI

526 DIRECT Consortium. Diabetologia. 2019 Sep 15;62(9):1601–15.

- 527 15. Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OT, Gunnarsdottir K,
- et al. Large-scale plasma proteomics comparisons through genetics and disease
 associations. Nature. 2023 Oct;622(7982):348–58.
- 530 16. Piening BD, Zhou W, Contrepois K, Röst H, Gu Urban GJ, Mishra T, et al. Integrative
- 531 Personal Omics Profiles during Periods of Weight Gain and Loss. Cell Syst. 2018
- 532 Feb;6(2):157-170.e8.
- Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The GenotypeTissue Expression (GTEx) project. Nat Genet. 2013 Jun 29;45(6):580–5.

535	18.	Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al.
536		Proteomics. Tissue-based map of the human proteome. Science. 2015 Jan
537		23;347(6220):1260419.
538	19.	Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The
539		STRING database in 2021: customizable protein-protein networks, and functional
540		characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021 Jan
541		8;49(D1):D605–12.
542	20.	Wang D, Day EA, Townsend LK, Djordjevic D, Jørgensen SB, Steinberg GR. GDF15:
543		emerging biology and therapeutic applications for obesity and cardiometabolic disease.
544		Nat Rev Endocrinol. 2021 Oct 11;17(10):592-607.
545	21.	Tsuchida C, Sakuramoto-Tsuchida S, Taked M, Itaya-Hironaka A, Yamauchi A, Misu
546		M, et al. Expression of REG family genes in human inflammatory bowel diseases and
547		its regulation. Biochem Biophys Rep. 2017 Dec;12:198–205.
548	22.	Zheng H chuan, Sugawara A, Okamoto H, Takasawa S, Takahashi H, Masuda S, et al.
549		Expression Profile of the REG Gene Family in Colorectal Carcinoma. Journal of
550		Histochemistry & Cytochemistry. 2011 Jan 23;59(1):106-15.
551	23.	Grün D, Lyubimova A, Kester L, Wiebrands K, Basak O, Sasaki N, et al. Single-cell
552		messenger RNA sequencing reveals rare intestinal cell types. Nature. 2015 Sep
553		10;525(7568):251–5.
554	24.	Sasaki N, Sachs N, Wiebrands K, Ellenbroek SIJ, Fumagalli A, Lyubimova A, et al.
555		Reg4 $^+$ deep crypt secretory cells function as epithelial niche for Lgr5 $^+$ stem cells in
556		colon. Proceedings of the National Academy of Sciences. 2016 Sep 13;113(37).
557	25.	Aihara E, Engevik KA, Montrose MH. Trefoil Factor Peptides and Gastrointestinal
558		Function. Annu Rev Physiol. 2017 Feb 10;79(1):357-80.

559	26.	Xue Y, Shen L, Cui Y, Zhang H, Chen Q, Cui A, et al. Tff3, as a Novel Peptide,
560		Regulates Hepatic Glucose Metabolism. PLoS One. 2013 Sep 23;8(9):e75240.
561	27.	Fueger PT, Schisler JC, Lu D, Babu DA, Mirmira RG, Newgard CB, et al. Trefoil
562		Factor 3 Stimulates Human and Rodent Pancreatic Islet β -Cell Replication with
563		Retention of Function. Molecular Endocrinology. 2008 May 1;22(5):1251-9.
564	28.	Mehner C, Radisky ES. Bad Tumors Made Worse: SPINK1. Front Cell Dev Biol.
565		2019 Feb 4;7.
566	29.	Pfützer RH, Barmada MM, Brunskill APJ, Finch R, Hart PS, Neoptolemos J, et al.
567		SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic
568		chronic pancreatitis. Gastroenterology. 2000 Sep;119(3):615-23.
569	30.	Rena G, Mordi IR, Lang CC. Metformin: still the sweet spot for CV protection in
570		diabetes? Curr Opin Pharmacol. 2020 Oct;54:202-8.
571	31.	Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, et al. Serum
572		tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J
573		Gastroenterol. 2010 Jan 30;45(1):52-9.
574	32.	Hu Y, Pan C, Hu J, Zhang S. The role of Reg IV in colorectal cancer, as a potential
575		therapeutic target. Współczesna Onkologia. 2015;4:261-4.
576	33.	Mohtar M, Syafruddin S, Nasir S, Low TY. Revisiting the Roles of Pro-Metastatic
577		EpCAM in Cancer. Biomolecules. 2020 Feb 7;10(2):255.
578	34.	Lyu J, Jiang M, Zhu Z, Wu H, Kang H, Hao X, et al. Identification of biomarkers and
579		potential therapeutic targets for pancreatic cancer by proteomic analysis in two
580		prospective cohorts. Cell Genomics. 2024 May;100561.
581		
582		
583		

Page | 25













